Karla Hostetler, APRN
Nurse Practitioner · Hesston, KSNPI 1669436366
Payments from drug & device makers
Across 134 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$415
- Lilly USA, LLC$252
- Amgen$252
- AstraZeneca$232
- Pfizer$163
- GSK$154
- plus $862 from 23 others
What the payments were for
- Food & beverage$2,331100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 23 | $415 |
| Lilly USA, LLC | 17 | $252 |
| Amgen | 13 | $252 |
| AstraZeneca | 10 | $232 |
| Pfizer | 10 | $163 |
| GSK | 9 | $154 |
| Novo Nordisk | 8 | $130 |
| Johnson & Johnson | 9 | $125 |
| Medtronic | 4 | $96 |
| Abbott | 4 | $80 |
| Sumitomo Pharma America, Inc. | 3 | $51 |
| Boehringer Ingelheim | 3 | $40 |
| Corcept Therapeutics | 2 | $40 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| Merck | 2 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Lundbeck LLC | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Insulet Corporation | 1 | $22 |
| Apria Healthcare LLC | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Novartis | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Collegium Pharmaceutical, Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Mylan Specialty L.p. | 1 | $11 |
How this compares
$2,331 in reported general payments places this provider in the 85th percentile of 1,326 nurse practitioner providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 228 | $113,582 |
| OzempicSemaglutide | 66 | $63,280 |
| MounjaroTirzepatide | 46 | $46,365 |
| JardianceEmpagliflozin | 44 | $37,759 |
| FarxigaDapagliflozin Propanediol | 54 | $30,991 |
| GemtesaVibegron | 97 | $26,234 |
| Breo ElliptaFluticasone/Vilanterol | 45 | $21,093 |
| MyrbetriqMirabegron | 78 | $20,721 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $19,808 |
| XareltoRivaroxaban | 52 | $18,107 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $15,749 |
| LinzessLinaclotide | 40 | $14,554 |
| QuliptaAtogepant | 14 | $10,988 |
| EntrestoSacubitril/Valsartan | 26 | $9,697 |
| Oxtellar XrOxcarbazepine | 26 | $8,930 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $163 | $113,582228 claims |
| Novo NordiskOzempic | $130 | $63,28066 claims |
| Lilly USA, LLCMounjaro | $252 | $46,36546 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $154 | $40,90174 claims |
| Boehringer IngelheimJardiance | $40 | $37,75944 claims |
| AstraZenecaFarxiga | $232 | $30,99154 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $51 | $26,23497 claims |
| AbbVieLinzess, Qulipta | $415 | $25,54254 claims |
| Johnson & JohnsonXarelto | $125 | $18,10752 claims |
| NovartisEntresto | $13 | $9,69726 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,326 nurse practitioner providers in Kansas.
Other nurse practitioner in Hesston
- Gary GrafTopeka$726K
- Sarah FitzmauriceKansas City$247K
- Anna ShortRoeland Park$215K
- Shannon GreggTopeka$140K
- Morteza RabiiOverland Park$88K
- Constance JacobWichita$65K
- Michelle KirkHutchinson$58K
- Catherine PowellWichita$50K
- Lori RanalloWestwood$48K
- Kristyn MilburnPleasanton$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.